EUCTR2009-014415-12-PL进行中（未招募）不适用
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 604
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects eligible for enrolment in the study must meet all of the following criteria:
- •1. Male or female subjects aged >=12, =65 years old with a minimum weight of 45Kg. [For countries where local regulations or the regulatory status of study medication permit enrolment of adults only, subjects recruited will be >=18 years].
- •2. Subjects with the clinical features of severe refractory asthma similar to those indicated in the ATS Workshop on Refractory Asthma [Proceeding of ATS workshop, 2000] for >=12 months prior to Visit 1 and mandated through meeting Inclusion Criteria 3, 4 and 5.
- •3. Subjects with a well-documented requirement for regular treatment with high
- •dose ICS [i.e. = 880 µg/day fluticasone propionate (FP) or equivalent daily], with or
- •without maintenance oral corticosteroids (OCS), in the 12 months prior to Visit 1. View protocol page 20.
- •4. Subjects with a well-documented requirement for regular treatment with high dose ICS [i.e. =880 mcg/day fluticasone propionate (FP) or equivalent daily], with or without maintenance oral corticosteroids (OCS), in the 12 months prior to Visit 1.
- •5. Subjects with persistent airflow obstruction as indicated by a pre-bronchodilator FEV1 <80% predicted (NHANES III) recorded at Visit 1 or Visit 2 or peak flow diurnal variability of >20% on 3 or more days during the run-in period.
- •6. Subjects with airway inflammation which is likely to be eosinophilic in nature as indicated by one of the following characteristics demonstrated at Visit 1 or documented in the previous 12 months:
- •An elevated peripheral blood eosinophil level of >=300/µL that is related to asthma or • Sputum eosinophils >=3% or • Exhaled nitric oxide >=50 ppb or • Prompt deterioration of asthma control (based on documented clinical history or objective measures) following a =<25% reduction in regular maintenance dose of inhaled or oral corticosteroid dose in the previous 12 months
- •7. Subjects with a previously confirmed history of two or more asthma exacerbations requiring treatment with oral or systemic corticosteroids in the 12 months prior to Visit 1, despite the use of high-dose ICS and additional controller medication. For subjects receiving maintenance OCS with high-dose ICS plus controller, the OCS treatment for exacerbations must be a two-fold or greater increase in the dose of OCS.
- •8. Evidence of asthma as documented by either:
- •Airway reversibility (FEV1>=12% and 200 ml) demonstrated1 at Visit 1 or Visit 2 or documented in the previous 12 months OR
- •Airway hyperresponsiveness (PC20 of <8mg/mL or PD20 of <7.8 µ mol methacholine/histamine) documented in the 12 months prior to Visit 1 OR
- •Airflow variability in clinic FEV1 >=20% between two consecutive clinic visits documented in the 12 months prior to Visit 1 ( FEV1 recorded during an exacerbation will not be valid) OR
- •Airflow variability as indicated by >20% diurnal variability in peak flow observed on 3 or more days during the run-in.
- •1For reversibility testing at Visit 1 or Visit 2, the Maximum Post-bronchodilator procedure should be employed in accordance with the methodology used by Asthma Clinical Research Network (see Study Procedures Manual)
- •9. ECG assessment (either QTcB or QTcF, machine or manual overread, males or females);
- •QTc < 450msec or QTc < 480 msec for patients with Bundle Branch Block.
- •10. Liver Function Tests;
- •ALT<2 x ULN (upper limit of normal)
- •AST<2 x ULN
- •Alk Phos = 1.5 x ULN
- •Bilirubin = 1.5 x ULN (isolated bilirubin>1.5 ULN is acceptable i
排除标准
- •1. Current smokers or subjects with a smoking history of >=10 pack years (number of pack years = (number of cigarettes per day / 20) x number of years smoked).
- •2. Presence of a clinically important lung condition other than asthma. This includes current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or diagnoses of emphysema or chronic bronchitis (chronic obstructive pulmonary disease other than asthma) or a history of lung cancer.
- •3. Subjects with a diagnosis of malignancy or in the process of investigation for a malignancy. Subjects with a past medical history of malignancy can be allowed in the trial provided anyone with a diagnosis of a recurrent malignant tumour or having received treatment for a malignancy within 12 months are excluded.
- •4. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices or persistent jaundice), cirrhosis, and known biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones).
- •5. Subjects with a diagnosis of Churg-Strauss syndrome.
- •6. Subjects who have taken methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine or any experimental anti-inflammatory therapies within 3 months of screening.
- •7. Subjects who have received omalizumab [Xolair®] or any other any other biological for the treatment of inflammatory disease within 130 days of Visit 1.
- •8. Regular use of oral or systemic corticosteroids for diseases other than asthma within the past 12 months or any intra-articular, short-acting intramuscular corticosteroid with 1 month or intramuscular, long-acting depot corticosteroids within 3 months.
- •9. Subject with allergy/intolerance to the excipients in the mepolizumab formulation.
- •10. Subjects who have received treatment with an investigational drug within the past 30 days or five half-lives whichever is longer, prior to the first doses of study medication (this also includes investigational formulations of marketed products).
- •11. Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
- •12. Subjects who have clinically significant cardiovascular, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment
- •13. Subjects with a history (or suspected history) of alcohol misuse or substance abuse to 2 years prior to Visit 1.
- •14. Subjects with a parasitic infestation within 6 months prior to Week -2 (Visit 1).
- •15. Subjects with a known immunodeficiency (e.g. human immunodeficiency virus – HIV), other than that explained by the use of corticosteroids taken as therapy for asthma.
- •16. Subjects who are unable to follow study instructions such as dosing directions, study electronic diary (eDiary) completion, or use of a standard metered dose inhaler.
- •17. Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician’s recommendations.
- •18. Subjects who have previously participated in a study of mepolizumab and received study medication within 90 days prior to screening.
研究者
相似试验
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalised for volume overload and require intravenous diuretic therapy. - PROTECT {CKI-302}Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.MedDRA version: 9.1Level: LLTClassification code 10000803Term: Acute heart failureEUCTR2006-001637-18-SEovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)1,000
进行中（未招募）
不适用
A research study of a new drug (MT-102) for patients with weight loss and weakness (cachexia) related to lung or colorectal cancerCachexia related to stage III and IV non-small cell lung cancer and colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10064015Term: Cancer cachexiaSystem Organ Class: 100000004861EUCTR2010-022486-10-DEPsioxus Therapeutics Limited129
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.EUCTR2004-000369-37-DKGlaxoSmithKline Group of Companies411
进行中（未招募）
1 期
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder. - LAMDAAttention Deficit Hyperactivity Disorder (ADHD)Classification code 10003731EUCTR2004-000730-37-CZJanssen-Cilag Medical Affairs EMEA
进行中（未招募）
1 期
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.EUCTR2009-014415-12-GBGlaxoSmithKline Research & Development Ltd